Jean A. Frazier, MD was 1 of 4 principal investigators in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study, a randomized, double-blind, multisite trial funded by the National Institute of Mental Health. The study, published in November 2008, compared the efficacy and tolerability of 3 antipsychotics—olanzapine, risperidone, and molindone—in pediatric patients with schizophrenia or schizoaffective disorder.

Dr. Frazier discusses the unexpected findings of the TEOSS trial with Current Psychiatry Section Editor Robert A. Kowatch, MD, PhD. Based on the trial findings and her experience, she tells how she makes decisions when prescribing antipsychotics for children and adolescents with schizophrenia and related disorders.

No comments:

Post a Comment

Discuss Current Psychiatry articles on www.facebook.com/CurrentPsychiatry
To read and participate in discussions of articles in Current Psychiatry, visit http://www.facebook.com/CurrentPsychiatry.
This site features discussions of articles from the April 2011 issue and earlier.
For free full-text access to all articles in Current Psychiatry visit http://www.currentpsychiatry.com.

CURRENT PSYCHIATRY reaches approximately 40,000 practicing psychiatrists, residents, advanced practice nurses, and faculty members in office, clinic, and hospital settings. Our mission is to provide psychiatrists with peer-reviewed, practical advice by leading authorities, emphasizing up-to-date solutions to common clinical problems.